Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2036-06-02 | Direct | 17,786 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,786 · Balance 17,786 F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 16,562 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy family trust | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 131,372 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-06-09 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 10,034 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.96 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 13,489 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.47 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 144,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.22 · Expires 2032-01-20 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Disposition to issuer · Disposed 115,500 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.34 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2021 Filed Jun 28, 2021 23:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,083 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-21-043574 · doc4.xml · derivative · entry 9 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,347 Underlying: Common Stock · 3,083 shares Expires 2027-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 23:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,017 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-21-043574 · doc4.xml · derivative · entry 8 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,166 Underlying: Common Stock · 17,017 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 23:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,647 | $29.14 | $77,133.05 |
DisclosureSEC source: 0001209191-21-043574 · doc4.xml · nonDerivative · entry 6 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 23:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 17,453 | $27.97 | $488,165.65 |
DisclosureSEC source: 0001209191-21-043574 · doc4.xml · nonDerivative · entry 5 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,977 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.80 to $28.71. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 23:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 3,083 | $0.53 | $1,633.99 |
DisclosureSEC source: 0001209191-21-043574 · doc4.xml · nonDerivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 23:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 17,017 | $1.24 | $21,101.08 |
DisclosureSEC source: 0001209191-21-043574 · doc4.xml · nonDerivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 23:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-21-043574 · doc4.xml · derivative · entry 7 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,183 Underlying: Common Stock · 100 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 23:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 100 | $27.76 | $2,775.50 |
DisclosureSEC source: 0001209191-21-043574 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 23:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 100 | $1.24 | $124.00 |
DisclosureSEC source: 0001209191-21-043574 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 17, 2021 Filed Jun 23, 2021 00:24 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-21-042594 · doc4.xml · derivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,283 Underlying: Common Stock · 200 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| June 17, 2021 Filed Jun 23, 2021 00:24 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 200 | $27.75 | $5,550.00 |
DisclosureSEC source: 0001209191-21-042594 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 17, 2021 Filed Jun 23, 2021 00:24 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 200 | $1.24 | $248.00 |
DisclosureSEC source: 0001209191-21-042594 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 00:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 23,019 | $26.02 | $599,067.17 |
DisclosureSEC source: 0001209191-21-041176 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By charitable remainder trust Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.62 to $26.47. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 00:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 14,003 | $25.92 | $362,921.35 |
DisclosureSEC source: 0001209191-21-041176 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By charitable remainder trust Disclosed balance after: 23,019 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.70 to $26.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2021 Filed Jun 25, 2021 21:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 11,650 | $0.00 Strike: $40.37 | $0.00 |
DisclosureSEC source: 0001209191-21-043334 · doc4.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 11,650 shares Expires 2031-06-07 F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 01:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,975 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0000899243-21-012695 · doc4.xml · derivative · entry 7 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,430 Underlying: Common Stock · 1,975 shares Expires 2027-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly. Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 01:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,625 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0000899243-21-012695 · doc4.xml · derivative · entry 6 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,483 Underlying: Common Stock · 2,625 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 01:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 4,600 | $27.87 | $128,181.30 |
DisclosureSEC source: 0000899243-21-012695 · doc4.xml · nonDerivative · entry 5 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.8571 to $27.8739. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 01:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 1,975 | $0.53 | $1,046.75 |
DisclosureSEC source: 0000899243-21-012695 · doc4.xml · nonDerivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 01:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 2,625 | $1.24 | $3,255.00 |
DisclosureSEC source: 0000899243-21-012695 · doc4.xml · nonDerivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 05, 2021 Filed Mar 19, 2021 01:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GiftCommon Stock | 37,022 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-012695 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By charitable remainder trust Disclosed balance after: 37,022 Read SEC document |
| March 05, 2021 Filed Mar 19, 2021 01:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GiftCommon Stock | 37,022 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-012695 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 273,872 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 7,882 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-21-017020 · doc4.xml · derivative · entry 9 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,764 Underlying: Common Stock · 7,882 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1/48th of the total shares on February 28, 2018, and then 1/48th of the total shares vest at the end of each month thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 1,842 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001209191-21-017020 · doc4.xml · derivative · entry 8 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,842 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is 100% vested and exercisable. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 2,776 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001209191-21-017020 · doc4.xml · derivative · entry 7 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,776 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is 100% vested and exercisable. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 4,957 | $61.14 | $303,086.84 |
DisclosureSEC source: 0001209191-21-017020 · doc4.xml · nonDerivative · entry 5 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.90 to $61.80 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 7,543 | $60.55 | $456,754.30 |
DisclosureSEC source: 0001209191-21-017020 · doc4.xml · nonDerivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,957 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.89 to $60.88 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 7,882 | $0.60 | $4,729.20 |
DisclosureSEC source: 0001209191-21-017020 · doc4.xml · nonDerivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,842 | $0.40 | $736.80 |
DisclosureSEC source: 0001209191-21-017020 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 2,776 | $0.40 | $1,110.40 |
DisclosureSEC source: 0001209191-21-017020 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:59 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $22.34 | $0.00 |
DisclosureSEC source: 0001209191-21-007774 · doc4.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 1, 2021 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 20:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | ConversionSeries A Preferred Stock · Derivative | 35,337 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036976 · doc4.xml · derivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 0 Underlying: Common Stock · 16,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 20:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | ConversionCommon Stock | 16,751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036976 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 310,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 14,777 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001209191-20-034732 · doc4.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,777 Underlying: Common Stock · 14,777 shares Expires 2030-06-02 F1 · derivative.exercise_date: The option shall fully vest on June 3, 2021 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| September 10, 2019 Filed Sep 13, 2019 00:06 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 14,777 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0001567619-19-018221 · doc1.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,777 Underlying: Common Stock · 14,777 shares Expires 2029-09-09 F1 · derivative.exercise_date: This option vests 100% and becomes exercisable on June 21, 2020, subject to reporting person's continued service through such vesting date Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.